MedTrace Logo

Phase II Trial of Thalidomide Combined With Concurrent Chemoradiotherapy in Esophageal Cancer

NCT01551641 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 180

Last updated 2016-02-17

No results posted yet for this study

Summary

The purpose of this study is to down-regulate VEGF expression in esophageal cancer patients by thalidomide, so to improve their chemoradiotherapy effect. Patients with esophageal cancer receiving chemoradiotherapy were divided into different sub-group according to dynamic change of their VEGF level,and those showed increased or unchanged VEGF were added thalidomide at random. Efficacy and side effect of thalidomide combined with chemoradiotherapy were evaluated, and at the same time, activity of thalidomide on esophageal cancer and its clinical safely were assessed.

Conditions

  • Esophageal Cancer

Interventions

OTHER

chemoradiotherapy

Patients only receive concurrent chemoradiotherapy if their serum VEGF level decrease.

DRUG

thalidomide

Patients will be given thalidomide combined with concurrent chemoradiotherapy if their serum VEGF level increase or unchanged.

OTHER

without thalidomide

Patients only receive concurrent chemoradiotherapy if their serum VEGF level increase or unchanged

Sponsors & Collaborators

  • Changzhou No.2 People's Hospital

    lead OTHER

Principal Investigators

  • Sun Suping, M.D.,PhD. · Changzhou No.2 People's Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-01-31
Primary Completion
2016-03-31
Completion
2016-03-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01551641 on ClinicalTrials.gov